tbuckley/cabot-search huggingface dataset:
Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia
Authors: Abhishek Maiti, Naval G. Daver
Journal: Clinical Cancer Research (2021)

Abstract Cellular therapies have demonstrated limited efficacy thus far in acute myeloid leukemia (AML). A recent study shows that mTOR complex 1 activation downregulated CXCR4 reducing marrow infiltration of EpCAM-targeting chimeric antigen receptor (CAR) T-cells in AML. Abrogating mTOR signaling by cotreatment with mTOR inhibitors during IL2-mediated ex vivo expansion upregulated CXCR4 and bolstered bone marrow migration and AML elimination by CAR T-cells. See related article by Nian et al., p. 6026
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas
Authors: M. Nieves Calvo-Vidal, Nahuel Zamponi, Jan Krumsiek, Max A. Stockslager, Maria V. Revuelta, Jude M. Phillip, Rossella Marullo, Ekaterina Tikhonova, Nikita Kotlov, Jayeshkumar Patel, Shao Ning Yang, Lucy Yang, Tony Taldone, Catherine Thieblemont, John P. Leonard, Peter Martin, Giorgio Inghirami, Gabriela Chiosis, Scott R. Manalis, Leandro Cerchietti
Journal: Cancer Research (2021)

HSP90 is critical for maintenance of the cellular proteostasis. In cancer cells, HSP90 also becomes a nucleating site for the stabilization of multiprotein complexes including signaling pathways and transcription complexes. Here we described the role of this HSP90 form, referred to as oncogenic HSP90, in the regulation of cytosolic metabolic pathways in proliferating B-cell lymphoma cells. Oncogenic HSP90 assisted in the organization of metabolic enzymes into non-membrane-bound functional compartments. Under experimental conditions that conserved cellular proteostasis, oncogenic HSP90 coordinated and sustained multiple metabolic pathways required for energy production and maintenance of cellular biomass as well as for secretion of extracellular metabolites. Conversely, inhibition of oncogenic HSP90, in absence of apparent client protein degradation, decreased the efficiency of MYC-driven metabolic reprogramming. This study reveals that oncogenic HSP90 supports metabolism in B-cell lymphoma cells and patients with diffuse large B-cell lymphoma, providing a novel mechanism of activity for HSP90 inhibitors. SIGNIFICANCE: The oncogenic form of HSP90 organizes and maintains functional multienzymatic metabolic hubs in cancer cells, suggesting the potential of repurposing oncogenic HSP90 selective inhibitors to disrupt metabolism in lymphoma cells.
Representation of Women and Underrepresented Groups in US Academic Medicine by Specialty
Authors: Alexander Yoo, Benjamin P. George, Peggy Auinger, Emma Strawderman, David A. Paul
Journal: JAMA Network Open (2021)

Linear mixed-effects models were used to estimate the mean change per year in percentages of women and percentages of underrepresented in medicine individuals and included department, time, and a department by time interaction, with an autoregressive AR(1) correlation structure for the repeated measures.d P value comparing slope to zero was < .003for all comparisons.e P value comparing slope to zero < .003.
Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes
Authors: Rune V. Overgaard, Christin L. Hertz, Steen H. Ingwersen, Andrea Navarria, Daniel J. Drucker
Journal: Cell Reports Medicine (2021)

Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for the treatment of type 2 diabetes. Whether clinically important responses and adverse events (AEs) are dependent on the route of administration has not been determined. We demonstrate that nearly identical exposure-response pharmacodynamic relationships are determined by plasma semaglutide levels achieved through oral versus injectable administration for changes in HbA1c, body weight, biomarkers of cardiovascular risk, and AEs such as nausea and vomiting. At typical exposure levels for oral semaglutide, the estimated response is 1.58% (oral) versus −1.62% (subcutaneous) for HbA1c and 3.77% (oral) versus 3.48% (subcutaneous) reduction in body weight relative to baseline after 6 months. Increased body weight is the most important variable associated with reduced semaglutide exposure for both formulations. Hence, interindividual variation in GLP-1R responsivity or route of administration are not major determinants of GLP-1RA effectiveness in the clinic.
Research Leaders Seek White House Role
Authors: Daniel S. Greenberg
Journal: New England Journal of Medicine (1974)

Readers of the few newspapers that pay attention to such matters may recently have encountered reports that the President has been advised that he needs full-time scientific counsel to replace the science adviser and attending staff that he dismissed in January, 1973, with the explanation that he could do without.Now, as is usually the case when a group or profession states the necessity for some of its own to be stationed at the supreme level of political affairs in this nation, there is more to the self-invitation than meets first glance. Such is the case here, and therefore, let . . .
The long non-coding RNA GHSROS mediates expression of genes associated with tumor growth, metastasis and adverse disease outcome
Authors: Patrick B. Thomas, Penny L. Jeffery, Eliza Whiteside, Carina Walpole, Michelle Maugham, Lidija Jovanovic, Jennifer H. Gunter, Colleen C. Nelson, Adrian C. Herington, Rakesh Veedu, Lisa K. Chopin, Inge Seim
Journal: Cancer Research (2017)

Long non-coding RNAs (lncRNAs) play key regulatory roles in cancer progression and are emerging therapeutic targets. The objective of this study was to investigate the expression and function of the lncRNA GHSROS in prostate cancer. Quantitative RT-PCR revealed that GHSROS is highly expressed in a subset of prostate cancers (Gleason score 8-10; z-score >1; Mann-Whitney-Wilcoxon test P=0.0021). Forced overexpression of the lncRNA stimulated cell migration in vitro in the PC3 (1.82 ± 0.35, P=0.006; Student’s t-test), DU145 (1.94 ± 0.34, P=0.017), and LNCaP (1.27 ± 0.02, P=0.0002) prostate cancer cell lines. Cell proliferation was increased in GHSROS overexpressing PC3 (3.36 ± 1.91, P=0.029), DU145 (1.749 ± 0.59, P=0.026), and LNCaP (1.39 ± 0.26, P=0.040) prostate cancer cell lines. These results were recapitulated in NOD/SCID mice, with increased tumor growth and Ki67 immunohistochemical staining in PC3 (P=0.0040) and DU145 (P = 0.036) xenografts overexpressing the lncRNA.High-throughput transcriptome sequencing (RNA-seq) identified 400 differentially expressed genes in GHSROS overexpressing PC3 cells, with enrichment of genes associated with motility, migration and regulation of cell growth. Further interrogation of the 400 gene set using Oncomine concept mapping, and interrogation of publicly-available clinical prostate cancer data sets, revealed a 34-gene signature associated with poorer disease outcome and metastatic progression. Preliminary analysis of The Cancer Genome Atlas (TCGA) data, suggest that the signature has potential as a prognostic indicator for disease free- or overall survival in numerous cancers. Finally, locked antisense oligonucleotide (LNA-ASO) inhibition of endogenous GHSROS reciprocally regulated cell growth (Student’s t-test; RNV124: -1.14 ± 0.06, P=0.049 and RNV104L: -1.18 ± 0.05, P=0.030, migration (RNV124: -1.96 ± 0.11, P=0.004) and gene expression changes, supporting the observations from forced GHSROS overexpression experiments.In summary, we provide evidence that GHSROS is a prostate cancer associated lncRNA that promotes a gene expression signature which enhances the propensity for metastasis and adverse disease outcomes. We also demonstrate that GHSROS can be targeted using antisense oligonucleotides. Further studies on this lncRNA may provide new prognostic and therapeutic opportunities.
How good is the evidence that cellular senescence causes skin ageing?
Authors: Evon Low, Ghazaleh Alimohammadiha, Lucy A. Smith, Lydia F. Costello, Stefan A. Przyborski, Thomas von Zglinicki, Satomi Miwa
Journal: Ageing Research Reviews (2021)

Skin is the largest organ of the body with important protective functions, which become compromised with time due to both intrinsic and extrinsic ageing processes. Cellular senescence is the primary ageing process at cell level, associated with loss of proliferative capacity, mitochondrial dysfunction and significantly altered patterns of expression and secretion of bioactive molecules. Intervention experiments have proven cell senescence as a relevant cause of ageing in many organs. In case of skin, accumulation of senescence in all major compartments with ageing is well documented and might be responsible for most, if not all, the molecular changes observed during ageing. Incorporation of senescent cells into in-vitro skin models (specifically 3D full thickness models) recapitulates changes typically associated with skin ageing. However, crucial evidence is still missing. A beneficial effect of senescent cell ablation on skin ageing has so far only been shown following rather unspecific interventions or in transgenic mouse models. We conclude that evidence for cellular senescence as a relevant cause of intrinsic skin ageing is highly suggestive but not yet completely conclusive.
転移性大腸癌のファーストライン治療としてのセツキシマブ+イリノテカン,フルオロウラシルおよびロイコボリン: 腫瘍KRASとBRAF突然変異ステータスによる全生存率分析の最新版
Authors: Van Cutsem Eric, Koehne Claus-Henning, Lang Istvan, Folprecht Gunnar, P Nowacki Marek, Cascinu Stefano, Shchepotin Igor, Maurel Joan, Cunningham David, Tejpar Sabine, Schlichting Michael, Zubel Angela, Celik Ilhan, Rougier Philippe, Ciardiello Fortunato
Journal: Journal of Clinical Oncology (2011)
Some disease-modifying osteoarthritis drugs make small improvements in knee and hip osteoarthritis
Authors: David S. Pisetsky
Journal: Annals of Internal Medicine (2021)

Source Citation Yang W, Sun C, He SQ, et al. The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis—a systematic review and network meta-analysis. J Gen Intern Med. 2021;36:2085-93. 33846938
Vaginal dysbiosis in pregnancy associates with risk of emergency caesarean section: a prospective cohort study
Authors: Thor Haahr, Tine Dalsgaard Clausen, Jonathan Thorsen, Morten A Rasmussen, Martin S Mortensen, Jenni Lehtimäki, Shiraz A Shah, Mathis H Hjelmsø, Klaus Bønnelykke, Bo L Chawes, Gisle Vestergaard, Bo Jacobsson, Per-Göran Larsson, Susanne Brix, Søren J Sørensen, Hans Bisgaard, Jakob Stokholm
Journal: Clinical Microbiology and Infection (2021)
活動性心サルコイドーシスにおける心筋障害の診断と検出に対する 123 I-BMIPPと 201 Tlミスマッチの臨床的意義
Authors: Momose Mitsuru, Fukushima Kenji, Kondoh Chisato, Serizawa Naoki, Suzuki Atsushi, Abe Koichiro, Hagiwara Nobuhisa, Sakai Shuji
Journal: Circulation (2015)
Association of Social Isolation With Disability Burden and 1-Year Mortality Among Older Adults With Critical Illness
Authors: Jason R. Falvey, Andrew B. Cohen, John R. O’Leary, Linda Leo-Summers, Terrence E. Murphy, Lauren E. Ferrante
Journal: JAMA Internal Medicine (2021)

Disability and mortality are common among older adults with critical illness. Older adults who are socially isolated may be more vulnerable to adverse outcomes for various reasons, including fewer supports to access services needed for optimal recovery; however, whether social isolation is associated with post-intensive care unit (ICU) disability and mortality is not known.
Abstract 11995: Sleep Duration and Excessive Daytime Sleepiness Are Associated With Obesity Independent of Lifestyle and Genetic Susceptibility
Authors: Andrea Maugeri, Marketa Sjogren, Olle Melander, Jose R Medina-Inojosa, Francisco Lopez, Manlio Vinciguerra
Journal: Circulation (2018)

Background: Sleep is a vital physiological process to maintain and promote good health. Irregular sleep patterns, such as short sleep duration or excessive daytime sleepiness (EDS), as well as diet...
C3-targeted therapy in periodontal disease: moving closer to the clinic
Authors: George Hajishengallis, Hatice Hasturk, John D. Lambris, Danae A. Apatzidou, Georgios N. Belibasakis, Nagihan Bostanci, Patricia M. Corby, Christopher W. Cutler, Francesco D’Aiuto, Evlambia Hajishengallis, Markus Huber-Lang, Effie Ioannidou, Tetsuhiro Kajikawa, Alpdogan Kantarci, Jonathan M. Korostoff, Georgios A. Kotsakis, Tomoki Maekawa, Dimitrios C. Mastellos, Niki M. Moutsopoulos, Srinivas Myneni, Richard Nagelberg, Bo Nilsson, Panos N. Papapanou, Evangelos Papathanasiou, Jan Potempa, Antonio Risitano, S. Esra Sahingur, Atsushi Saito, Anton Sculean, Andreas Stavropoulos, Flavia R. Teles, Maurizio Tonetti, Despina Yancopoulou
Journal: Trends in Immunology (2021)
Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment
Authors: Jung-Min Pyun, Young Ho Park, Keon-Joo Lee, SangYun Kim, Andrew J. Saykin, Kwangsik Nho
Journal: Translational Neurodegeneration (2021)

Abstract Background The combinatorial effect of multiple genetic factors calculated as a polygenic risk score (PRS) has been studied to predict disease progression to Alzheimer’s disease (AD) from mild cognitive impairment (MCI). Previous studies have investigated the performance of PRS in the prediction of disease progression to AD by including and excluding single nucleotide polymorphisms within the region surrounding the APOE gene. These studies may have missed the APOE genotype-specific predictability of PRS for disease progression to AD. Methods We analyzed 732 MCI from the Alzheimer’s Disease Neuroimaging Initiative cohort, including those who progressed to AD within 5 years post-baseline ( n = 270) and remained stable as MCI ( n = 462). The predictability of PRS including and excluding the APOE region (PRS + APOE and PRS − APOE ) on the conversion to AD and its interaction with the APOE ε4 carrier status were assessed using Cox regression analyses. Results PRS + APOE (hazard ratio [HR] 1.468, 95% CI 1.335–1.615) and PRS − APOE (HR 1.293, 95% CI 1.157–1.445) were both associated with a significantly increased risk of MCI progression to dementia. The interaction between PRS + APOE and APOE ε4 carrier status was significant with a P -value of 0.0378. The association of PRSs with the progression risk was stronger in APOE ε4 non-carriers (PRS + APOE : HR 1.710, 95% CI 1.244–2.351; PRS − APOE : HR 1.429, 95% CI 1.182–1.728) than in APOE ε4 carriers (PRS + APOE : HR 1.167, 95% CI 1.005–1.355; PRS − APOE : HR 1.172, 95% CI 1.020–1.346). Conclusions PRS could predict the conversion of MCI to dementia with a stronger association in APOE ε4 non-carriers than APOE ε4 carriers. This indicates PRS as a potential genetic predictor particularly for MCI with no APOE ε4 alleles.
What Are the Next Steps for Developing a National Steps Guideline?
Authors: Nicole L. Spartano
Journal: JAMA Network Open (2021)

Amanda E. Paluch, PhD; Kelley Pettee Gabriel, PhD; Janet E. Fulton, PhD; Cora E. Lewis, MD; Pamela J. Schreiner, PhD; Barbara Sternfeld, PhD; Stephen Sidney, MD; Juned Siddique, PhD; Kara M. Whitaker, PhD; Mercedes R. Carnethon, PhD
Abstract #917: Cardiac Mrp1 transporter mediates glutathione-conjugated 4-hydroxy-nonenal (GS-HNE) efflux in doxorubicin treated mice
Authors: Paiboon Jungsuwadee, Tian Yong Zhao, D Allan Butterfield, Daret St. Clair, Mary Vore
Journal: Cancer Research (2009)

Multidrug resistant-associated protein 1 (Mrp1, Abcc1; 190 kDa) mediates the ATP-dependent efflux of endo- and xenobiotics and is expressed in various tissues including heart. In mouse heart, Mrp1 is localized primarily in sarcolemma, where it is thought to mediate efflux of the glutathione conjugate of a highly reactive product of lipid peroxidation, 4-hydroxy-nonenal (HNE). We used Doxorubicin (DOX), an anthracycline chemotherapy drug, as a model to induce oxidative stress and lipid peroxidation that has been demonstrated to be associated with cardiac toxicity. Here, we were able to identify GS-HNE in cardiac mitochondria following DOX treatment. DOX also induced Mrp1 expression in both sarcolemma and cardiac mitochondria. The mitochondrial Mrp1 were capable of mediating ATP-dependent transport of Mrp1 substrates such as estradiol-17\#946;-glucuronide, leukotriene C4 and GS-HNE. The transport activities were inhibited by MK571, a selective Mrp1 inhibitor. Sarcolemma membrane vesicles isolated from DOX-treated mice showed similar transport activities for GS-HNE compared to saline controls. However, GS-HNE transport activity in SMP was increased 2-fold in DOX vs. saline treated-mice. A non-linear regression analysis of sarcolemma membrane vesicle transport from FVB wild-type mice yielded Km and Vmax values of 55.6 \#956;mol/L and 983.5 pmol/min/mg protein, respectively. No Mrp1 transport activity was observed in Mrp1-/- sarcolemma membrane vesicles, indicating that transport of GS-HNE was mediated by Mrp1. Thus, we demonstrate here that functional Mrp1 is localized in sarcolemma and mitochondria following DOX. Mrp1 may serve to protect the heart by mediating efflux of toxic products of oxidative stress such as highly reactive lipid peroxide, HNE from mitochondria and the cardiomyocyte.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 917.
The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical Trial
Authors: Hagen Schwenzer, Erica De Zan, Mustafa Elshani, Ruud van Stiphout, Mary Kudsy, Josephine Morris, Valentina Ferrari, In Hwa Um, James Chettle, Farasat Kazmi, Leticia Campo, Alistair Easton, Sebastian Nijman, Michaela Serpi, Stefan Symeonides, Ruth Plummer, David J. Harrison, Gareth Bond, Sarah P. Blagden
Journal: Clinical Cancer Research (2021)

Nucleoside analogues form the backbone of many therapeutic regimens in oncology and require the presence of intracellular enzymes for their activation. A ProTide is comprised of a nucleoside fused to a protective phosphoramidate cap. ProTides are easily incorporated into cells whereupon the cap is cleaved and a preactivated nucleoside released. 3'-Deoxyadenosine (3'-dA) is a naturally occurring adenosine analogue with established anticancer activity
Abstract 15094: Contemporary Patterns of Utilization of Ivabradine and Sacubitril/Valsartan Among Medicare Beneficiaries
Authors: Andrew Sumarsono, Ezimamaka Ajufo, Muthiah Vaduganathan, Sandeep R Das, Ambarish Pandey
Journal: Circulation (2019)

Introduction: The FDA approved the use of sacubitril/valsartan and ivabradine among patients with HF and reduced ejection fraction (HFrEF) in 2015. However, after market introduction, early experie...
Association of ECT With Risks of All-Cause Mortality and Suicide in Older Medicare Patients
Authors: Taeho Greg Rhee, Kyaw Sint, Mark Olfson, Tobias Gerhard, Susan H. Busch, Samuel T. Wilkinson
Journal: American Journal of Psychiatry (2021)

Objective: This observational study examined the effects of electroconvulsive therapy (ECT) on suicide and all-cause mortality risk in older psychiatric patients. Methods: Participants were Medicare-insured psychiatric inpatients age 65 or older. Patients receiving ECT were exact-matched to control subjects (in a 1:3 ratio) on age, gender, principal hospital diagnosis, past-year psychiatric hospitalizations, past-year suicide attempts, and Elixhauser comorbidity index. Cox proportional hazard models were risk-adjusted for race, year of hospitalization, rural-urban continuum code, year of index hospitalization, median income of zip code, and all matched covariates to estimate hazard ratios with 95% confidence intervals. Results: A total of 10,460 patients in the ECT group and 31,160 in the control group were included in the analyses (total N=41,620; 65.4% female; mean age, 74.7 years [SD=7.09]). Compared with the control group, patients receiving ECT had lower all-cause mortality for up to 1 year following hospital discharge (adjusted hazard ratio=0.61, 95% CI=0.56, 0.66). For death by suicide, 1-year survival analysis showed no group difference. A significant association was observed with suicide in the first months following ECT, but this pattern waned over time (1 month: hazard ratio=0.44, 95% CI=0.21, 0.91; 2 months: hazard ratio=0.52, 95% CI=0.29, 0.92; 3 months: hazard ratio=0.56, 95% CI=0.37, 0.92; 6 months: 0.87, 95% CI=0.59, 1.28; 12 months: 0.92, 95% CI=0.68, 1.25). Conclusions: In this observational study, ECT was associated with lower 1-year all-cause mortality and with short-lived protective effects on suicide risk. These findings support greater consideration of ECT for inpatients with mood disorders at short-term risk of suicide.
Leveraging advances in immunopathology and artificial intelligence to analyze in vitro tumor models in composition and space
Authors: Tze Ker Matthew Leong, Wen Shern Lo, Wei En Zen Lee, Benedict Tan, Xing Zhao Lee, Li Wen Justina Nadia Lee, Jia-Ying Joey Lee, Nivedita Suresh, Lit-Hsin Loo, Evan Szu, Joe Yeong
Journal: Advanced Drug Delivery Reviews (2021)
A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2
Authors: Mona O. Mohsen, Ina Balke, Simon Zinkhan, Villija Zeltina, Xuelan Liu, Xinyue Chang, Pascal S. Krenger, Kevin Plattner, Zahra Gharailoo, Anne‐Cathrine S. Vogt, Gilles Augusto, Marianne Zwicker, Salony Roongta, Dominik A. Rothen, Romano Josi, Joana J. da Costa, Jan M. Sobczak, Aleksandra Nonic, Lee‐Anne Brand, Katja Nuss, Byron Martina, Daniel E. Speiser, Thomas Kündig, Gary T. Jennings, Senta M. Walton, Monique Vogel, Andris Zeltins, Martin F. Bachmann
Journal: Allergy (2021)

Abstract Background SARS‐CoV‐2 caused one of the most devastating pandemics in the recent history of mankind. Due to various countermeasures, including lock‐downs, wearing masks, and increased hygiene, the virus has been controlled in some parts of the world. More recently, the availability of vaccines, based on RNA or adenoviruses, has greatly added to our ability to keep the virus at bay; again, however, in some parts of the world only. While available vaccines are effective, it would be desirable to also have more classical vaccines at hand for the future. Key feature of vaccines for long‐term control of SARS‐CoV‐2 would be inexpensive production at large scale, ability to make multiple booster injections, and long‐term stability at 4℃. Methods Here, we describe such a vaccine candidate, consisting of the SARS‐CoV‐2 receptor‐binding motif (RBM) grafted genetically onto the surface of the immunologically optimized cucumber mosaic virus, called CuMV TT ‐RBM. Results Using bacterial fermentation and continuous flow centrifugation for purification, the yield of the production process is estimated to be &gt;2.5 million doses per 1000‐litre fermenter run. We demonstrate that the candidate vaccine is highly immunogenic in mice and rabbits and induces more high avidity antibodies compared to convalescent human sera. The induced antibodies are more cross‐reactive to mutant RBDs of variants of concern (VoC). Furthermore, antibody responses are neutralizing and long‐lived. In addition, the vaccine candidate was stable for at least 14 months at 4℃. Conclusion Thus, the here presented VLP‐based vaccine may be a good candidate for use as conventional vaccine in the long term.
Transforming Canada's role in global cancer control
Authors: Danielle Rodin, Anna J Dare, Reanne Booker, Christopher Booth, Heather Bryant, Ophira Ginsburg, Meredith Giuliani, Mary Gospodarowicz, Sumit Gupta, Nazik Hammad, Zeev Rosberger, Simon Sutcliffe, Craig C Earle
Journal: The Lancet Oncology (2021)
Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B
Authors: Heejoon Jang, Jun Sik Yoon, Soo Young Park, Han Ah Lee, Myoung-jin Jang, Seung Up Kim, Dong Hyun Sinn, Yeon Seok Seo, Hwi Young Kim, Sung Eun Kim, Dae Won Jun, Eileen L. Yoon, Joo Hyun Sohn, Sang Bong Ahn, Jae-Jun Shim, Soung Won Jeong, Yong Kyun Cho, Hyoung Su Kim, Joon Yeul Nam, Yun Bin Lee, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim, Pietro Lampertico, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Thomas Berg, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Harry LA. Janssen, George V. Papatheodoridis, Jeong-Hoon Lee
Journal: Clinical Gastroenterology and Hepatology (2021)